314 related articles for article (PubMed ID: 31941831)
1. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.
Parikh AR; Mojtahed A; Schneider JL; Kanter K; Van Seventer EE; Fetter IJ; Thabet A; Fish MG; Teshome B; Fosbenner K; Nadres B; Shahzade HA; Allen JN; Blaszkowsky LS; Ryan DP; Giantonio B; Goyal L; Nipp RD; Roeland E; Weekes CD; Wo JY; Zhu AX; Dias-Santagata D; Iafrate AJ; Lennerz JK; Hong TS; Siravegna G; Horick N; Clark JW; Corcoran RB
Clin Cancer Res; 2020 Apr; 26(8):1877-1885. PubMed ID: 31941831
[TBL] [Abstract][Full Text] [Related]
2. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
3. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.
Ma F; Guan Y; Yi Z; Chang L; Li Q; Chen S; Zhu W; Guan X; Li C; Qian H; Xia X; Yang L; Zhang J; Husain H; Liao Z; Futreal A; Huang J; Yi X; Xu B
Int J Cancer; 2020 Mar; 146(5):1359-1368. PubMed ID: 31241775
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
5. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner N
Ann Oncol; 2019 Jun; 30(6):945-952. PubMed ID: 30860573
[TBL] [Abstract][Full Text] [Related]
6. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
Khakoo S; Carter PD; Brown G; Valeri N; Picchia S; Bali MA; Shaikh R; Jones T; Begum R; Rana I; Wotherspoon A; Terlizzo M; von Loga K; Kalaitzaki E; Saffery C; Watkins D; Tait D; Chau I; Starling N; Hubank M; Cunningham D
Clin Cancer Res; 2020 Jan; 26(1):183-192. PubMed ID: 31852830
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
8. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M
Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.
Boonstra PA; Ter Elst A; Tibbesma M; Gietema JA; Schuuring E; Reyners AKL
Oncologist; 2019 Jun; 24(6):e387-e390. PubMed ID: 30670599
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
11. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
12. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
[No Abstract] [Full Text] [Related]
13. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
[TBL] [Abstract][Full Text] [Related]
14. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer.
Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
Sci Rep; 2019 Nov; 9(1):17358. PubMed ID: 31758080
[TBL] [Abstract][Full Text] [Related]
15. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
Lyskjær I; Kronborg CS; Rasmussen MH; Sørensen BS; Demuth C; Rosenkilde M; Johansen AFB; Knudsen M; Vang S; Krag SRP; Spindler KG; Andersen CL
Sci Rep; 2019 Aug; 9(1):11542. PubMed ID: 31395942
[TBL] [Abstract][Full Text] [Related]
16. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
Forthun RB; Hovland R; Schuster C; Puntervoll H; Brodal HP; Namløs HM; Aasheim LB; Meza-Zepeda LA; Gjertsen BT; Knappskog S; Straume O
Sci Rep; 2019 Nov; 9(1):17471. PubMed ID: 31767937
[TBL] [Abstract][Full Text] [Related]
17. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
18. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer.
Chen C; Wang T; Yang M; Song J; Huang M; Bai Y; Su H
Pathol Oncol Res; 2021; 27():1609879. PubMed ID: 34720757
[No Abstract] [Full Text] [Related]
19. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
Coombes RC; Page K; Salari R; Hastings RK; Armstrong A; Ahmed S; Ali S; Cleator S; Kenny L; Stebbing J; Rutherford M; Sethi H; Boydell A; Swenerton R; Fernandez-Garcia D; Gleason KLT; Goddard K; Guttery DS; Assaf ZJ; Wu HT; Natarajan P; Moore DA; Primrose L; Dashner S; Tin AS; Balcioglu M; Srinivasan R; Shchegrova SV; Olson A; Hafez D; Billings P; Aleshin A; Rehman F; Toghill BJ; Hills A; Louie MC; Lin CJ; Zimmermann BG; Shaw JA
Clin Cancer Res; 2019 Jul; 25(14):4255-4263. PubMed ID: 30992300
[TBL] [Abstract][Full Text] [Related]
20. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]